gdp versus eshap regimen in relapsed and/or refractory hodgkin lymphoma: a comparison study.
نویسندگان
چکیده
despite multiple published studies reporting result of salvage regimens for relapsed and refractory hodgkin's lymphoma, there are no comparisons of different combinations.a total of 44 patients identified with refractory or relapsed hodgkin's lymphoma were considered eligible for this study. the patients were randomly divided into two groups of 22, one of which were treated with gdp regimen (gemcitabine, dexamethasone and cisplatin) and the other with ehsap regimen (etoposide, methyl prednisolone, cisplatin and cytarabine) in a prospective manner. the results of each group were compared.there were 27.3% complete response, 31.8% more than 50% response, and 40.9% no response with gdp. eshap results were 29.5%, 24% and 45.5%, respectively.there is no significant difference in response rate between gdp and eshap regimens as salvage chemotherapy in refractory or relapsed hodgkin's lymphoma.
منابع مشابه
correction: gdp versus eshap regimen in relapsed and/or refractory hodgkin lymphoma: a comparison study
#no abstract#
متن کاملGDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study
BACKGROUND Despite multiple published studies reporting result of salvage regimens for relapsed and refractory Hodgkin's lymphoma, there are no comparisons of different combinations. PATIENTS AND METHODS A Total of 44 patients identified with refractory or relapsed Hodgkin's Lymphoma were considered eligible for this study. The Patients were randomly divided into two groups of 22, one of whic...
متن کاملCost-Utility Analysis of IEV Drug Regimen Versus ESHAP Drug Regimen for the Patients With Relapsed and Refractory Hodgkin and Non-Hodgkin’s Lymphoma in Iran
BACKGROUND Chemotherapy for lymph nodes cancer is often composed of several drugs that are used in a treatment program. OBJECTIVES The aim of this study was to perform a cost-utility analysis of IEV regimen (ifosfamide, epirubicin and etoposide) versus ESHAP regimen (etoposide, methylprednisolone, high-dose cytarabine, and cisplatin) in patients with lymphoma in the south of Iran. PATIENTS ...
متن کاملiev (ifosfamide, epirubicin, vp16) regimen as salvage therapy for early relapsed/refractory non-hodgkin/hodgkin lymphoma
introduction: management of early relapsed or refractory lymphoma [hodgkin & non- hodgkin lymphoma (hl & nhl)] is a matter of problem, especially when hematopietic stem cell support is not available. the aim of this study was to evaluate effectiveness of iev regimen ( ifosfamide, epirubicin, vp16), in lymphoma patients who are not candidate for stem cell transplantation. because the majority of...
متن کاملESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma.
The ESHAP regimen, a combination of the chemotherapeutic drugs etoposide, methylprednisolone (solumedrol), high-dose cytarabine (ara-C), and cisplatin, has been shown to be active against refractory or relapsed non-Hodgkin's lymphoma (NHL) in therapeutic trials. We undertook this study to determine whether this regimen would be effective and tolerable in Korean patients. A total of 40 patients ...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
international journal of hematology-oncology and stem cell researchجلد ۹، شماره ۱، صفحات ۱۰-۱۴
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023